Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyzeRCTsin oncology

被引:20
作者
Ristl, Robin [1 ]
Ballarini, Nicolas M. [1 ]
Goette, Heiko [2 ]
Schueler, Armin [2 ]
Posch, Martin [1 ]
Koenig, Franz [1 ]
机构
[1] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[2] Merck Healthcare KGaA, Darmstadt, Germany
关键词
LOG-RANK TEST; FLEMING-HARRINGTON CLASS; SEQUENTIAL-TESTS; END-POINTS; WEIGHTS;
D O I
10.1002/pst.2062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non-proportionality. We model these sources of non-proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log-rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non-proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non-proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non-proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests.
引用
收藏
页码:129 / 145
页数:17
相关论文
共 34 条
  • [1] Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
    Anagnostou, Valsamo
    Yarchoan, Mark
    Hansen, Aaron R.
    Wang, Hao
    Verde, Franco
    Sharon, Elad
    Collyar, Deborah
    Chow, Laura Q. M.
    Forde, Patrick M.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 4959 - 4969
  • [2] [Anonymous], 2011, COUNTING PROCESSES S
  • [3] [Anonymous], 2018, PUBL WORKSH ONC CLIN
  • [4] Sequential tests for non-proportional hazards data
    Brueckner, Matthias
    Brannath, Werner
    [J]. LIFETIME DATA ANALYSIS, 2017, 23 (03) : 339 - 352
  • [5] Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
    Chan, David Lok Hang
    Segelov, Eva
    Wong, Rachel S. H.
    Smith, Annabel
    Herbertson, Rebecca A.
    Li, Bob T.
    Tebbutt, Niall
    Price, Timothy
    Pavlakis, Nick
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (06):
  • [6] Predicting analysis times in randomized clinical trials with cancer immunotherapy
    Chen, Tai-Tsang
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16
  • [7] Statistical issues and challenges in immuno-oncology
    Chen, Tai-Tsang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2013, 1
  • [8] On the interpretation of the hazard ratio in Cox regression
    De Neve, Jan
    Gerds, Thomas A.
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 742 - 750
  • [9] Lessons from randomized phase III studies with active cancer immunotherapies - Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)
    Finke, Lothar H.
    Wentworth, Kerry
    Blumenstein, Brent
    Rudolph, Natalie S.
    Levitsky, Hyarn
    Hoos, Axel
    [J]. VACCINE, 2007, 25 : B97 - B109
  • [10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092